{"entity":{"id":"nct07367516","kind":"trial","name":"Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer","aka":[],"tldr":"A phase 1/2 trial of TQB6411 in oesophageal cancer, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., now recruiting.","summary":"Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer is a phase 1/2 interventional study registered as NCT07367516 by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., with 105 participants planned, started 2026-02-12 and due to reach its primary completion in 2027-02. Interventions recorded: TQB6411 Injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07367516","url":"https://clinicaltrials.gov/study/NCT07367516"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["esophageal"],"sections":[],"technologies":[],"targets":[],"drugs":["tqb6411"],"companies":["sino-biopharm"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07367516","phase":"1/2","setting":"A Phase Ib/II Clinical Trial Evaluating the Safety and Efficacy of TQB6411 Injection in Participant s With Recurrent or Metastatic Esophageal Cancer Who Have Failed Prior PD-1/PD-L1 Inhibitor Plus Platinum-Based Chemotherapy","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","enrolled":105,"outcomes":[]},"route":"/trials/nct07367516/","neighbours":{"cancer":[{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"}],"drug":[{"id":"tqb6411","kind":"drug","name":"TQB6411","route":"/drugs/tqb6411/"}],"company":[{"id":"sino-biopharm","kind":"company","name":"Sino Biopharmaceutical (Chia Tai Tianqing)","route":"/companies/sino-biopharm/"}]}}